The black box warning for topical calcineurin inhibitors: looking outside the box
- 31 July 2006
- journal article
- review article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 97 (1) , 117-120
- https://doi.org/10.1016/s1081-1206(10)61381-6
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- The “black box” warning and allergy drugsJournal of Allergy and Clinical Immunology, 2006
- Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?British Journal of Dermatology, 2005
- Review of the potential photo‐cocarcinogenicity of topical calcineurin inhibitorsJournal of the European Academy of Dermatology and Venereology, 2005
- Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic DermatitisDermatology, 2005
- Consensus Statement on the Safety Profile of Topical Calcineurin InhibitorsDermatology, 2005
- Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2005
- Atopic DermatitisNew England Journal of Medicine, 2005
- Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimusJournal of Dermatological Treatment, 2005
- Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in ChildrenPediatrics, 2002
- Tacrolimus (FK506): New treatment approach in superantigen-associated diseases like atopic dermatitis?Journal of Allergy and Clinical Immunology, 2001